

TARGET

Intelligence Report

VOLUME XXVI No. 168

T U E S D A Y

August 6, 2024

SHENZHEN HEPALINK PHARMACEUTICAL GROUP COMPANY LTD: THE CHAIRMAN IS SUED FOR BREACHES OF CONTRACTS

The Chairman of Shenzhen Hepalink Pharmaceutical Group Company Ltd (深圳市海普瑞藥業集團股份有限公司) (Code: 9989, Main Board, The Stock Exchange of Hongkong Ltd), Mr Li Li (李鋰), has been sued in The High Court of the Hongkong Special Administrative Region (HKSAR) of The People's Republic of China (PRC) for \$US45,075,363.00 (about \$HK352,128,735.76).

Mr He Jiao Zi is the Plaintiff in Action Number 1473 of 2024, lodged in Court of First Instance of The High Court of the HKSAR, on or about Friday, July 26, 2024.

The address of the Plaintiff is given in the Writ of Summons as being:

House Number One,
Number 11, Plantation Road,
The Peak,
Hongkong.

With regard to the Hongkong address of the Defendant, it is said in the recitals of the Writ of Summons, that his last known address was:

Room Number 4276,
42nd Floor,
Sun Hung Kai Centre,
Number 30, Harbour Road,
Wanchai,
Hongkong.

In the Writ of Summons, a '**GENERAL INDORSEMENT OF CLAIM**' was attached, hereby copied verbatim:

'The Plaintiff claims against the Defendant for breach of contracts entered into between the parties, namely Service Agreement dated 5 October 2023 and the Settlement Agreement dated 13 May 2024 and undertakings given by the Defendant on diver dates, under which as at 22 June 2024, the Defendant failed to pay to the Plaintiff the outstanding amount in the sum

of US\$45,075,363.00 and 1.8% of all the issued share capital of the company known as Shenzhen Hepalink Pharmaceutical Group Co.td. (深圳市海普瑞藥業集團股份有限公司), listed on the Shenzhen Stock Exchange with stock code 002399 and also listed on the Hong Kong Stock Exchange with stock code 9989.

‘AND THE PLAINTIFF CLAIMS AGAINST THE DEFENDANT FOR:-

- ‘(1) An order that the Defendant do pay the sum of US\$45,075,363.00 (or equivalent amount in Hong Kong dollars) to the Plaintiff;*
- ‘(2) An order that the Defendant do transfer to the Plaintiff or her nominee 1.8% of all the issued share capital of the company known as Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(深圳市海普瑞藥業集團股份有限公司), listed on the Shenzhen Stock Exchange with stock code 002399 and also listed on the Hong Kong Stock Exchange with stock code 9989;*
- ‘(3) Alternatively, an order that the Defendant do pay the Plaintiff damages to be assessed arising from or in connection with the Defendant's failure to transfer the said 1.8% of all the issued share capital of the company known as Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (深圳市海普瑞藥業集團股份有限公司), listed on the Shenzhen Stock Exchange with stock code 002399 and also listed on the Hong Kong Stock Exchange with stock code 9989;*
- ‘(4) Interest;*
- ‘(5) Costs; and*
- ‘(6) Further or other reliefs.’*

For the sake of clarity, in addition to the listing of the Company’s shares on the Main Board, The Stock Exchange of Hongkong Ltd, where the Hongkong Stock Code is Number 9989, the Issued Share Capital of Shenzhen Hepalink Pharmaceutical Group Company Ltd is, also, listed on The Shenzhen Stock Exchange, its Stock Code, being Number 002399.

THE POSITIVE ALERT

On or about Friday, July 12, 2024, in Shenzhen, The People’s Republic of China, Mr Li Li, acting in his august position as Chairman of Shenzhen Hepalink Pharmaceutical Group Company Ltd, caused to publish and disseminate the following four-page ***‘POSITIVE PROFIT ALERT ANNOUNCEMENT FOR THE ESTIMATED 2024 INTERIM RESULTS’***:

***‘POSITIVE PROFIT ALERT
ANNOUNCEMENT FOR THE ESTIMATED
2024 INTERIM RESULTS***

*'This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**") pursuant to the requirements of Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) for the purpose of providing shareholders of the Company (the "**Shareholders**") and the public with the financial information of the Company. This announcement is also published in accordance with Rule 13.10B of the Listing Rules as it is also published on the Shenzhen Stock Exchange.*

*'The following is the estimated interim results for the six months ended June 30, 2024 ("**Reporting Period**") of the Company together with its subsidiaries (the "**Group**"). The financial data contained in this results estimate has not been audited and is, except for non-IFRSs (International Financial Reporting Standards) adjusted net profit attributable to shareholders ... [CLICK TO ORDER FULL ARTICLE](#)*

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

*If readers feel that they would like to voice their opinions about that which they have read in **TARGET**, please feel free to e-mail your views to editor@targetnewspapers.com. **TARGET** does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.*